PrimeraDx Enters Multiyear Relationship with Eli Lilly
By LabMedica International staff writers Posted on 02 Jul 2012 |
PrimeraDx (Mansfield, MA, USA), a molecular diagnostics company, has entered into a multiyear relationship with Eli Lilly and Co. (Indianapolis, IN, USA) to develop diagnostic products in support of multiple clinical development programs for novel therapeutics. The two companies will collaborate to develop multiplex assays on PrimeraDx's clinical platform, the ICEPlex System.
PrimeraDx has developed and is commercializing a novel, clinical platform that combines polymerase chain reaction (PCR) with capillary electrophoresis. The result of combining the two technologies into a bench-top instrument is the ability to deliver highly multiplexed, multimodal, and quantitative answers to the clinic.
A key advantage of this next-generation quantitative PCR technology is the ability to rapidly configure very complex multimodal assays that test for contrasting target types, such as single-nucleotide polymorphisms (SNPs), expression biomarkers, microRNAs, and fusion genes.
Dr. Matt McManus, president and CEO of PrimeraDx said, "This relationship really moves our company forward in achieving our goals of bringing personalized medicine to the clinic and being the leader in the high-value companion diagnostics space. These programs are a tremendous validation of our technology and its utility in the development of complex tests to better diagnose and treat patients. "
"Our early focus will be in oncology, but as with all of our early research, we will apply learnings across therapeutic areas," added Dr. Schade.
Related Links:
PrimeraDx
Eli Lilly and Co.
PrimeraDx has developed and is commercializing a novel, clinical platform that combines polymerase chain reaction (PCR) with capillary electrophoresis. The result of combining the two technologies into a bench-top instrument is the ability to deliver highly multiplexed, multimodal, and quantitative answers to the clinic.
A key advantage of this next-generation quantitative PCR technology is the ability to rapidly configure very complex multimodal assays that test for contrasting target types, such as single-nucleotide polymorphisms (SNPs), expression biomarkers, microRNAs, and fusion genes.
Dr. Matt McManus, president and CEO of PrimeraDx said, "This relationship really moves our company forward in achieving our goals of bringing personalized medicine to the clinic and being the leader in the high-value companion diagnostics space. These programs are a tremendous validation of our technology and its utility in the development of complex tests to better diagnose and treat patients. "
"Our early focus will be in oncology, but as with all of our early research, we will apply learnings across therapeutic areas," added Dr. Schade.
Related Links:
PrimeraDx
Eli Lilly and Co.
Latest Industry News
- ECCMID Congress Name Changes to ESCMID Global
- Bosch and Randox Partner to Make Strategic Investment in Vivalytic Analysis Platform
- Siemens to Close Fast Track Diagnostics Business
- Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics
- Sysmex and Hitachi Collaborate on Development of New Genetic Testing Systems
- Sysmex and CellaVision Expand Collaboration to Advance Hematology Solutions
- BD and Techcyte Collaborate on AI-Based Digital Cervical Cytology System for Pap Testing
- Medlab Middle East 2024 to Address Transformative Potential of Artificial Intelligence
- Seegene and Microsoft Collaborate to Realize a World Free from All Diseases and Future Pandemics
- Medlab Middle East 2024 to Highlight Importance of Sustainability in Laboratories
- Fujirebio and Agappe Collaborate on CLIA-Based Immunoassay
- Medlab Middle East 2024 to Highlight Groundbreaking NextGen Medicine
- bioMérieux Acquires Software Company LUMED to Support Fight against Antimicrobial Resistance
- Roche Acquires LumiraDx's Point of Care Technology for USD 295 Million
- Bruker Acquires IVD Manufacturer ELITech Group and Cell Imaging Company Phasefocus
- AMP Publishes Best Practice Guidance for Slice Testing Approach in Diagnostics